OncoMed Pharmaceuticals (OMED) Earning Somewhat Favorable Media Coverage, Report Finds
Press coverage about OncoMed Pharmaceuticals (NASDAQ:OMED) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoMed Pharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.2819480114038 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of OncoMed Pharmaceuticals (OMED) opened at 4.25 on Friday. OncoMed Pharmaceuticals has a 52 week low of $2.91 and a 52 week high of $12.58. The stock’s market cap is $159.93 million. The firm has a 50-day moving average price of $3.62 and a 200-day moving average price of $5.55.
OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The business had revenue of $6.20 million for the quarter, compared to analyst estimates of $6.08 million. During the same quarter last year, the business earned ($0.91) EPS. OncoMed Pharmaceuticals’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, analysts forecast that OncoMed Pharmaceuticals will post ($1.85) earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the company. Piper Jaffray Companies set a $5.00 price objective on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, July 10th. Jefferies Group LLC reissued a “buy” rating and set a $5.00 price objective on shares of OncoMed Pharmaceuticals in a research report on Sunday, July 9th. ValuEngine downgraded OncoMed Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. HC Wainwright lowered their price objective on OncoMed Pharmaceuticals from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, May 15th. Finally, Cantor Fitzgerald set a $6.00 price objective on OncoMed Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. OncoMed Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.00.
In other news, Director Jonathan D. Root sold 13,880 shares of OncoMed Pharmaceuticals stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $3.71, for a total value of $51,494.80. Following the completion of the transaction, the director now owns 121,020 shares in the company, valued at approximately $448,984.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Perry A. Karsen bought 10,000 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was purchased at an average price of $3.46 per share, with a total value of $34,600.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $34,600. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 64,614 shares of company stock valued at $222,249. 32.80% of the stock is owned by insiders.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.